Study Demonstrates One Administration of Synvisc® Improves Osteoarthritis Pain
		Genzyme announced today that preliminary results from a new study indicate that patients using Synvisc®(hylan G-F 20) through a single-dose regimen achieved a statistically significant improvement in pain from osteoarthritis of the knee over 26 weeks compared with those using placebo. Currently Synvisc is delivered through three intra-articular administrations given at one-week intervals. For more information, please read the press release.

		Genzyme Retains Separate Medicare Code and Reimbursement Rate for Synvisc®
		Genzyme Corp. (Nasdaq: GENZ) today announced that Synvisc® (hylan G-F 20), a market-leading viscosupplement used to treat pain due to osteoarthritis of the knee, will maintain a separate reimbursement code and rate for 2007. For more information, please read the press release.